Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New plaster aims to soothe chemo side effect

NCT ID NCT07501442

Symptom relief Sponsor: Wooshin Labottach Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a plaster containing uracil can reduce symptoms of hand-foot syndrome (HFS) in adults undergoing chemotherapy. HFS causes redness, swelling, and pain on the hands and feet. Researchers will compare the uracil plaster to a standard soothing cream. About 80 participants will use the treatment 2-3 times daily for 3 weeks and track their symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Both sexes; * Aged over 18 years; * Willing and able to return to the study site for post-procedural assessments; * Agree to take precautions to prevent pregnancy (applicable only to non-menopausal female subjects), including abstinence, intrauterine device (IUD), progestin implants, combined estrogen-progestin contraceptives, or condom use; * Agree to sign the informed consent form. * With HFS of grade I and II severity due to chemotherapy Self-sufficient with Performance Status of 0, 1, 2 according with the EOCG table. * Red blood cells folate test and serum folate test- Independent Biomarkers performed and to polymorphism testing DPD before starting therapy with dihydro pyrimidines. Exclusion criteria * Patients with grade III severity according to of HFS severity (Hand-Foot Syndrome- NCI-CTCAE v.0 Severity Grading. * ECOG Performance Status Scale = 3 or 4 * Pregnancy (applicable only to non-menopausal female subjects); * Breastfeeding (applicable only to non-menopausal female subjects); * Non-menopausal female subjects not using the specified contraceptive measures to prevent pregnancy during the study; * Sensitivity or allergy to the investigational product or its components (to be assessed by the investigator at baseline); * Predicted poor compliance with study protocol; * Participation in a similar study currently or within the past 3 months; * Dermatological clinical conditions that could interfere with performance outcomes; * Current pharmacological treatment with: * Medications that may affect test results as deemed by the investigator. * Use of other medications not mentioned above can be authorized by the investigator. Trade name, dosage, start and end dates of therapy will be documented in the concomitant medication form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hand-foot syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hand-foot syndrome hyaline fibromatosis syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HFS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Presidio Ospedaliero Di Rho - Asst Rhodense- Oncology Department

    Rho, MI, 20017, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.